Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter observational study collects real-world outcomes from adults with metastatic NSCLC who receive amivantamab plus platinum-based chemotherapy through an early access program. It enrolls two cohorts: Cohort A includes patients with EGFR exon 20 insertions treated with the combination as first-line therapy, and Cohort B includes patients with EGFR exon 19 or 21 mutations treated with the combination after prior osimertinib. Investigators will record time to disease progression (progression-free survival), other clinical outcomes, and safety events using routine clinical data. The study is non-randomized and aims to describe effectiveness and tolerability across participating French hospitals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient over 18 years old
* Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.
* Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.
* Patient covered by the French National Health Insurance system or by an approved third-party payer
* Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)

Exclusion Criteria:

* Patient placed under legal guardianship or subject to a protective legal measure
* Patient who explicitly refuses the collection or use of their personal data for research purposes
* Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator

Where it's running

• CH du Pays d Aix - Service des Maladies Respiratoires
  Aix-en-Provence, France Recruiting
• APHP Hôpital Avicennes
  Bobigny, France Recruiting
• Pneumologie Centre Hospitalier Intercommunal de Créteil
  Créteil, France Recruiting
• Hôpital A. Mignot
  Le Chesnay, France Recruiting
• Pneumologie Hôpital Calmette
  Lille, France Recruiting
• Pneumologie Hôpital privé Jean Mermoz
  Lyon, France Recruiting

Study contacts

• Principal investigator: Prof. Jean-Bernard Auliac — Service de Pneumologie - Centre Hospitalier Intercommunal de Créteil
• Study coordinator: Prof. Laurent Greillier
• Email: a.boucheix@g-f-p-c.org
• Phone: +33 4 73 98 39 86

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• Understanding resistance to amivantamab in lung cancer patients

  This study is trying to understand why some lung cancer patients with a specific mutation stop responding to the drug amivantamab, by looking at their blood and tumor samples after their disease gets worse.

  Recruiting at 10 sites Groupe Francais De Pneumo-Cancerologie · Bordeaux and 17 other locations · NCT06247826

• Targeted radiation therapy for advanced lung cancer

  This study is testing if adding a special type of radiation therapy to regular drug treatment can help people with advanced lung cancer that has spread to the liver feel better and live longer.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Miami, Florida and 8 other locations · NCT05657873

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Befotertinib plus chemo with MRD-guided escalation for EGFR-mutant NSCLC

  This phase 2 trial tests whether starting befotertinib and then using MRD results to guide adding chemotherapy improves outcomes for adults with EGFR-mutant advanced NSCLC.

  Recruiting Phase 2 Guangzhou University of Traditional Chinese Medicine · Guangzhou, Guangdong and 1 other locations · NCT07709585

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.